57 search results for: asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe <b>Asthma</b>

Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients

Monitoring Lung Function Is an Important Aspect of Pediatric <b>Asthma</b> Management

interactivity

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

5 min

Pulmonology

Navigate through this interactive infographic to learn more about why lung function is important to monitor in pediatric patients with asthma and the noninvasive procedures that are available for implementation in clinical practice.

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe <b>Asthma</b> – Patient Case Introduction

expert video

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

10 min

Pulmonology

In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Leonard Bacharier describes a typical patient presentation in the pediatric asthma clinic and explores whether clinical remission is a goal of treatment for this patient and others like them.

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe <b>Asthma</b> – Patient Case Follow-Up

expert video

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up

5 min

Pulmonology

In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Leonard Bacharier revisits a patient case study where a biologic has been added to an asthma management plan and describes the potential for this patient to achieve on-therapy clinical remission.

Podcast

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

22 min

Pulmonology

Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.

How Can FeNO Support the Management of Pediatric <b>Asthma</b>?

expert video

How Can FeNO Support the Management of Pediatric Asthma?

2 min

Pulmonology

Dr. Michael Blaiss discusses the importance of measuring FeNO in pediatric asthma patients.

Eosinophils as a Biomarker for Type 2 <b>Asthma</b>

expert video

Eosinophils as a Biomarker for Type 2 Asthma

15 min

Pulmonology

Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.

FeNO as a Biomarker for Type 2 <b>Asthma</b>

expert video

FeNO as a Biomarker for Type 2 Asthma

16 min

Pulmonology

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric <b>Asthma</b> in Children 6-11 Years of Age

interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

5 min

Pulmonology

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

On-Treatment Clinical Remission in <b>Asthma</b> Patients Case Tool

interactivity

On-Treatment Clinical Remission in Asthma Patients Case Tool

7 min

Pulmonology

Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.

What is the Role of FeNO as an <b>Asthma</b> Biomarker?

expert video

What is the Role of FeNO as an Asthma Biomarker?

2 min

Pulmonology

Prof. Klaus Rabe and Dr. Michael Wechsler explore the utility of FeNO as a biomarker in asthma.

IgE as a Biomarker for Type 2 <b>Asthma</b>

expert video

IgE as a Biomarker for Type 2 Asthma

14 min

Pulmonology

Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Hong KongChange country/region